Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis

Thrombosis and Haemostasis

Volumn 103, Issue 4, 2010, Pages 841-848

  Sofi, Francesco ^a,b,c   Marcucci, Rossella ^a   Gori, Anna Maria ^a,b,c   Giusti, Betti ^a   Abbate, Rosanna ^a   Gensini, Gian Franco ^a,b,c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Antiplatelet therapy; Clinical recurrences; Clopidogrel; Meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; LOADING DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PUBLICATION BIAS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77952075376     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-06-0418     Document Type: Article

References (29)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 71-86.
2. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
3. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005; 46: 761-769. (Pubitemid 41224796)
4. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621. (Pubitemid 41552416)
5. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
6. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability. Tex Heart Inst J 2008; 35: 313-320.
7. Sofi F, Marcucci R, Gori AM, et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events. A meta-analysis. Int J Cardiol 2008; 128: 166-171.
8. Snoep JD, Hovens MMC, Eikenboom JCJ, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231. (Pubitemid 47069129)
9. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787. (Pubitemid 36603418)
10. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3064-3067.
11. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826. (Pubitemid 41579802)
12. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromes. J Thromb Haemost 2006; 4: 542-549.
13. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary sindrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345. (Pubitemid 44436814)
14. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary implantation. Eur Heart J 2006; 27: 2420-2425. (Pubitemid 44522148)
15. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750. (Pubitemid 44648629)
16. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317. (Pubitemid 46891710)
17. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843. (Pubitemid 47555077)
18. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334. (Pubitemid 350239106)
19. Price MJ, Endemamm S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
20. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2008; 52: 1128-1133.
21. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaenous coronary intervention with drug-eluting stent. Thromb Res 2008; doi:10.1016/j.thromres.2008.10.007
22. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12 month follow-up. Circulation 2009; 119: 237-242.
23. Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99: 1518-1522. (Pubitemid 46770633)
24. Gori AM, Marcucci R, Migliorini A, et al. Impact and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
25. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-1064. (Pubitemid 351339490)
26. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 2009; epub ahead of print.
27. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; epub ahead of print.
28. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients udergoing coronary stent placement. Heart 2001; 85: 92-93. (Pubitemid 32973418)
29. Wolfram RM, Torguson RL, Hassani SE, et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006; 97: 984-989.